Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Tables)

Segment reporting (Tables)

9 Months Ended

Apr. 30, 2014

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended April 30, 2014
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	14,542			—			—			—		$	14,542
Product revenues		—		$	8,707			—			—			8,707
Royalty and license fee income		—			729			—			—			729
		14,542			9,436			—			—			23,978
Operating expenses:
Cost of clinical laboratory services		9,784			—			—			—			9,784
Cost of product revenues		—			3,800			—			—			3,800
Research and development		—			599		$	250			—			849
Selling, general and administrative		5,091			3,278			—		$	2,236			10,605
Provision for uncollectible accounts receivable		684			—			—			—			684
Legal fee expense		282			766						863			1,911
Legal settlements, net		2,000			(5,100	)		—			—			(3,100	)
Total operating expenses		17,841			3,343			250			3,099			24,533

Operating income (loss)		(3,299	)		6,093			(250	)		(3,099	)		(555	)

Other income (expense)
Interest		(10	)		4			—			(41	)		(47	)
Other		7			(2	)		—			5			10
Foreign currency gain		—			144			—			—			144
Income (loss) before income taxes	$	(3,302	)	$	6,239		$	(250	)	$	(3,135	)	$	(448	)

Depreciation and amortization included above	$	351		$	614		$	—		$	23		$	988

Share-based compensation included in above:
Cost of clinical laboratory services	$	2			1			—			—		$	3
Research and development		—			—			—			—			—
Selling, general and administrative		9		$	(4	)		—		$	275			280
Total	$	11		$	(3	)		—		$	275		$	283

Capital expenditures	$	90		$	36		$	—		$	—		$	126

Three months ended April 30, 2013
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	13,384			—			—			—		$	13,384
Product revenues		—		$	8,265			—			—			8,265
Royalty and license fee income		—			949			—			—			949
		13,384			9,214			—			—			22,598
Operating expenses:
Cost of clinical laboratory services		9,331			—			—			—			9,331
Cost of product revenues		—			4,219			—			—			4,219
Research and development		61			625		$	303			—			989
Selling, general and administrative		5,041			3,813			—		$	2,178			11,032
Provision for uncollectible accounts receivable		887			41			—			—			928
Legal fee expense		115			21			—			1,572			1,708
Total operating expenses		15,435			8,719			303			3,750			28,207

Operating income (loss)		(2,051	)		495			(303	)		(3,750	)		(5,609	)

Other income (expense)
Interest		(12	)		2			—			—			(10	)
Other		6			12			—			7			25
Foreign currency gain		—			(214	)		—			—			(214	)
Income (loss) before income taxes	$	(2,057	)	$	295		$	(303	)	$	(3,743	)	$	(5,808	)

Depreciation and amortization included above	$	354		$	778		$	4		$	25		$	1,161

Share-based compensation included in above:
Cost of clinical laboratory services	$	2			—			—			—		$	2
Research and development		—			1			—			—			1
Selling, general and administrative		11		$	—			—		$	126			137
Total	$	13		$	1			—		$	126		$	140

Capital expenditures	$	148		$	18		$	—		$	—		$	166

Nine months ended April 30, 2014
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	43,250			—			—			—		$	43,250
Product revenues		—		$	24,424			—			—			24,424
Royalty and license fee income		—			3,366			—			—			3,366
		43,250			27,790			—			—			71,040
Operating expenses:
Cost of clinical laboratory services		28,785			—			—			—			28,785
Cost of product revenues		—			11,511			—			—			11,511
Research and development		14			1,668		$	816			—			2,498
Selling, general and administrative		15,122			10,098			—		$	5,997			31,217
Provision for uncollectible accounts receivable		2,448			20			—			—			2,468
Legal fees expense		572			803			—			3,413			4,788
Legal settlements, net		2,000			(5,100	)								(3,100	)
Total operating expenses		48,941			19,000			816			9,410			78,167

Operating income (loss)		(5,691	)		8,790			(816	)		(9,410	)		(7,127	)

Other income (expense)
Interest		(32	)		13			—			(142	)		(161	)
Other		34			18			—			33			85
Foreign currency gain		—			460			—			—			460
Income (loss) before income taxes	$	(5,689	)	$	9,281		$	(816	)	$	(9,519	)	$	(6,743	)

Depreciation and amortization included above	$	1,061		$	1,876		$	6		$	72		$	3,015

Share-based compensation included in above:
Cost of clinical laboratory services	$	6		$	1			—			—		$	7
Research and development		—			1			—			—			1
Selling, general and administrative		28			5			—		$	456			489
Total	$	34		$	7			—		$	456		$	497

Capital expenditures	$	453		$	117		$	—		$	—		$	570

Nine months ended April 30, 2013
	Clinical Labs			Life Sciences		Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	41,881			—		—			—		$	41,881
Product revenues		—		$	24,574		—			—			24,574
Royalty and license fee income		—			3,982		—			—			3,982
		41,881			28,556		—			—			70,437
Operating expenses:
Cost of clinical laboratory services		28,466			—		—			—			28,466
Cost of product revenues		—			12,546		—			—			12,546
Research and development		236			1,800	$	932			—			2,968
Selling, general and administrative		14,914			12,165		—		$	6,261			33,340
Provision for uncollectible accounts receivable		3,656			201		—			—			3,857
Legal fee expense		272			58		—			4,520			4,850
Total operating expenses		47,544			26,770		932			10,781			86,027

Operating income (loss)		(5,663	)		1,786		(932	)		(10,781	)		(15,590	)

Other income (expense)
Interest		(34	)		6		—			3			(25	)
Other		31			32		—			18			81
Foreign currency gain		—			119		—			—			119
Income (loss) before income taxes	$	(5,666	)	$	1,943	$	(932	)	$	(10,760	)	$	(15,415	)

Depreciation and amortization included above	$	1,017		$	2,382	$	19		$	79		$	3,497

Share-based compensation included in above:
Cost of clinical laboratory services	$	7			—		—			—		$	7
Research and development		—		$	2		—			—			2
Selling, general and administrative		37			6		—		$	389			432
Total	$	44		$	8		—		$	389		$	441

Capital expenditures	$	579		$	193	$	—		$	—		$	772

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details